Corvus Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
CRVS Corvus Pharmaceuticals Inc
NRSN Neurosense Therapeutics Ltd
ACNT Ascent Industries Co
FATH Fathom Digital Manufacturing Corp
PAYX Paychex Inc
WAVD Wavedancer Inc
RNXT RenovoRx Inc
GBNY Generations Bancorp NY Inc
POL Polished.Com Inc
MDGS Medigus Ltd

Health Care : Biotechnology | Small Cap Value
Company profile

Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on development of immune modulator product candidates with the potential to treat solid cancers, T cell lymphomas, autoimmune, allergic and infectious diseases. Its lead product candidate is CPI-818, a selective, covalent inhibitor of ITK and is in a multi-center Phase 1/1b clinical trial in patients with various malignant T cell lymphomas. Its second product candidate, ciforadenant, is an oral, small molecule antagonist of the A2A receptor for adenosine designed to disable a tumor’s ability to subvert attack by the immune system by blocking the binding of immunosuppressive adenosine in the tumor microenvironment to the A2A receptor. Its third product candidate is mupadolimab, a humanized monoclonal antibody that is designed to react with a specific site on CD73. Its product candidate also includes CPI-182, an Anti-CXCR2 Antibody designed to block inflammation and myeloid suppression.

Day's Change
0.06 (4.26%)
B/A Size
Day's High
Day's Low

Today's volume of 44,477 shares is on pace to be much lighter than CRVS's 10-day average volume of 188,271 shares.




All providers

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.